Showing results 1 to 1 of 1
| Title | Author(s) | Issue Date | |
|---|---|---|---|
Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong Journal:Cost Effectiveness and Resource Allocation | 2020 |